Xuebijing injection combined with alprostadil in the treatment of diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis
Na Hao,Yang Liu,LuXuan Guo,Wanwen Li,Pengbo Zhao
DOI: https://doi.org/10.1097/md.0000000000032095
IF: 1.6
2024-06-15
Medicine
Abstract:Background: Diabetes nephropathy (DN), as one of the common complications of diabetes, is characterized by persistent albuminuria, decreased glomerular filtration rate, and elevated arterial blood pressure. At present, Xuebijing injection is widely used in the treatment of DN. However, few systematic reviews and meta-analysis related to Xuebijing injection intervention in DN were published. In order to more systematically and objectively evaluate the clinical efficacy of Xuebijing injection intervention in DN, we conducted systematic reviews and meta-analysis to verify it. Objective: The purpose of the research was to systematically evaluate the clinical efficacy of Xuebijing injection combined with alprostadil in the treatment of diabetic nephropathy. Methods: We searched the China National Knowledge Infrastructure (CNKI), China Biomedical Database (SinoMed), Weipu Database (VIP), Wanfang Database, PubMed, The Cochrane Library, Embase, Web of Science and other databases by computer, and searched the randomized controlled trials of Xuebijing injection combined with alprostadil in the treatment of DN at home and abroad from the establishment of the database to 2022. The main outcome indicators included blood glucose, and the secondary outcome indicators included blood lipid, renal function, urinary protein, and safety. Two evaluators independently screened the literature, extracted the data and evaluated the risk of bias in the included studies. RevMan 5.3 software was used to analyze the data. Results: A total of 14 randomized controlled trials were included, including 1233 cases, 618 cases in the treatment group and 615 cases in the control group. The results of meta-analysis demonstrated that compared with the control group, the treatment group could effectively reduce fasting plasma glucose [mean difference [MD] = −1.90, 95% CI (−2.40, −1.40), P < .00001], glycosylated hemoglobin A1c [MD = −2.38, 95% CI (−2.51, −2.25), P < .00001], 2h postprandial blood glucose [MD = −2.92, 95% CI (−3.95, −1.89), P < .00001], triacylglycerol [MD = −1.08, 95% CI (−1.66, −0.50), P = .0003], total cholesterol [MD = −1.17, 95% CI (−1.39, −0.95), P < .00001], low-density lipoprotein cholesterol [MD = −1.19, 95% CI (−1.60, −0.78), P < .00001], high-density lipoprotein cholesterol [MD = 0.32, 95% CI (0.23, 0.42), P < .00001], serum creatinine [MD = −42.95, 95% CI (−57.46, −28.43), P < .00001], blood urea nitrogen [MD = −2.24, 95%CI (−2.62,−1.86), P < .00001], blood β2 microglobulin [SMD = −1.49, 95% CI (−1.70, −1.28), P < .00001], urine β2 microglobulin [SMD = −0.81, 95% CI (−1.04, −0.58), P < .00001], 24-hour urinary protein quantification [MD = −0.20, 95% CI (−0.26, −0.14), P < .00001], urinary albumin excretion rate [SMD = −1.15, 95% CI (−1.38, −0.93), P < .00001]. Conclusion: Xuebijing injection combined with alprostadil has more advantages in treating DN compared to routine Western medicine.
medicine, general & internal